HDVY Forms Agreement for Developing Laboratory Tests for Breast Cancer Therapy Selection with Quest Diagnostics Print E-mail
By Staff and Wire Reports   
Wednesday, 17 March 2010 12:12

Health Discovery Corporation (OTCBB: HDVY) (HDC) and Smart Personalized Medicine, LLC (SPM) announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic testing, information and services. Under the agreements, Quest Diagnostics will develop new laboratory tests for aiding in the selection of breast cancer therapies.

Under the terms of the agreements, HDC and SPM will receive upfront licensing payments, development fees and royalties on a per test basis from Quest Diagnostics.

In February 2009, Health Discovery Corporation announced that it had licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter